CN100502911C - 一种抗风湿药物及其制备方法 - Google Patents
一种抗风湿药物及其制备方法 Download PDFInfo
- Publication number
- CN100502911C CN100502911C CNB028286421A CN02828642A CN100502911C CN 100502911 C CN100502911 C CN 100502911C CN B028286421 A CNB028286421 A CN B028286421A CN 02828642 A CN02828642 A CN 02828642A CN 100502911 C CN100502911 C CN 100502911C
- Authority
- CN
- China
- Prior art keywords
- weight portion
- eluent
- water
- herba epimedii
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003814 drug Substances 0.000 title claims abstract description 115
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 241001197778 Tripterygium hypoglaucum Species 0.000 claims abstract description 67
- 238000000034 method Methods 0.000 claims abstract description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 81
- 239000003480 eluent Substances 0.000 claims description 61
- 239000000843 powder Substances 0.000 claims description 54
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 52
- 239000000284 extract Substances 0.000 claims description 41
- 239000007788 liquid Substances 0.000 claims description 40
- 210000000582 semen Anatomy 0.000 claims description 39
- 239000002775 capsule Substances 0.000 claims description 35
- 239000000796 flavoring agent Substances 0.000 claims description 31
- 235000019634 flavors Nutrition 0.000 claims description 31
- 238000002156 mixing Methods 0.000 claims description 24
- 239000012567 medical material Substances 0.000 claims description 22
- 239000011347 resin Substances 0.000 claims description 22
- 229920005989 resin Polymers 0.000 claims description 22
- 238000003809 water extraction Methods 0.000 claims description 22
- 230000003356 anti-rheumatic effect Effects 0.000 claims description 19
- 239000003435 antirheumatic agent Substances 0.000 claims description 19
- 230000002879 macerating effect Effects 0.000 claims description 19
- 238000010828 elution Methods 0.000 claims description 17
- 239000002994 raw material Substances 0.000 claims description 17
- 230000000274 adsorptive effect Effects 0.000 claims description 15
- 239000012634 fragment Substances 0.000 claims description 12
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 12
- 238000006243 chemical reaction Methods 0.000 claims description 11
- TZJALUIVHRYQQB-XLRXWWTNSA-N icariin Chemical compound C1=CC(OC)=CC=C1C1=C(O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)C(=O)C2=C(O)C=C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-XLRXWWTNSA-N 0.000 claims description 11
- TZJALUIVHRYQQB-UHFFFAOYSA-N icariine Natural products C1=CC(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(C)O2)O)C(=O)C2=C(O)C=C(OC3C(C(O)C(O)C(CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-UHFFFAOYSA-N 0.000 claims description 11
- 238000005520 cutting process Methods 0.000 claims description 10
- 229920002472 Starch Polymers 0.000 claims description 9
- 239000008107 starch Substances 0.000 claims description 9
- 235000019698 starch Nutrition 0.000 claims description 9
- 238000001802 infusion Methods 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 8
- 235000017784 Mespilus germanica Nutrition 0.000 claims description 7
- 235000000560 Mimusops elengi Nutrition 0.000 claims description 7
- 235000007837 Vangueria infausta Nutrition 0.000 claims description 7
- -1 alkaloid compound Chemical class 0.000 claims description 7
- 238000011010 flushing procedure Methods 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 238000010521 absorption reaction Methods 0.000 claims description 5
- 238000005267 amalgamation Methods 0.000 claims description 5
- 238000010298 pulverizing process Methods 0.000 claims description 5
- 238000005303 weighing Methods 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 4
- 238000005516 engineering process Methods 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- OGYXOOJUJQIDOX-FVCAYHPDSA-N 5-hydroxy-2-(4-hydroxyphenyl)-8-(3-methylbut-2-enyl)-7-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxychromen-4-one Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC1=C(C=2C=CC(O)=CC=2)OC2=C(CC=C(C)C)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC(O)=C2C1=O OGYXOOJUJQIDOX-FVCAYHPDSA-N 0.000 claims description 3
- 229940123907 Disease modifying antirheumatic drug Drugs 0.000 claims description 3
- IYCPMVXIUPYNHI-UHFFFAOYSA-N Icariside I Natural products C1=CC(OC)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(OC3C(C(O)C(O)C(CO)O3)O)C(CC=C(C)C)=C2O1 IYCPMVXIUPYNHI-UHFFFAOYSA-N 0.000 claims description 3
- NGMYNFJANBHLKA-SENBMHEBSA-N Icariside II Natural products O(C)c1ccc(C2=C(O[C@H]3[C@@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)C(=O)c3c(O)cc(O)c(C/C=C(\C)/C)c3O2)cc1 NGMYNFJANBHLKA-SENBMHEBSA-N 0.000 claims description 3
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims description 3
- 229930013930 alkaloid Natural products 0.000 claims description 3
- 239000012141 concentrate Substances 0.000 claims description 3
- 150000004141 diterpene derivatives Chemical class 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- OGYXOOJUJQIDOX-UHFFFAOYSA-N epimedoside A Natural products OC1C(O)C(O)C(C)OC1OC1=C(C=2C=CC(O)=CC=2)OC2=C(CC=C(C)C)C(OC3C(C(O)C(O)C(CO)O3)O)=CC(O)=C2C1=O OGYXOOJUJQIDOX-UHFFFAOYSA-N 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 229930003944 flavone Natural products 0.000 claims description 3
- 150000002212 flavone derivatives Chemical class 0.000 claims description 3
- 235000011949 flavones Nutrition 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 150000003648 triterpenes Chemical class 0.000 claims description 3
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 240000002624 Mespilus germanica Species 0.000 claims 3
- 238000001179 sorption measurement Methods 0.000 claims 2
- 206010018367 Glomerulonephritis chronic Diseases 0.000 claims 1
- 241000236488 Lepra Species 0.000 claims 1
- 206010024229 Leprosy Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 33
- 230000001225 therapeutic effect Effects 0.000 abstract description 8
- 244000013539 Cuscuta australis Species 0.000 abstract description 2
- 241000110637 Cuscuta chinensis Species 0.000 abstract description 2
- 241001362421 Epimedium brevicornu Species 0.000 abstract description 2
- 244000241838 Lycium barbarum Species 0.000 abstract description 2
- 235000015459 Lycium barbarum Nutrition 0.000 abstract description 2
- 239000006049 herbal material Substances 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 59
- 241000699670 Mus sp. Species 0.000 description 55
- 241000699666 Mus <mouse, genus> Species 0.000 description 52
- 210000004027 cell Anatomy 0.000 description 33
- 229940079593 drug Drugs 0.000 description 28
- 238000002347 injection Methods 0.000 description 22
- 239000007924 injection Substances 0.000 description 22
- 230000002401 inhibitory effect Effects 0.000 description 21
- 230000037396 body weight Effects 0.000 description 19
- 206010070834 Sensitisation Diseases 0.000 description 17
- 230000008313 sensitization Effects 0.000 description 17
- 239000006285 cell suspension Substances 0.000 description 16
- 238000003304 gavage Methods 0.000 description 15
- 239000002671 adjuvant Substances 0.000 description 13
- 230000003203 everyday effect Effects 0.000 description 12
- 239000006228 supernatant Substances 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 230000036039 immunity Effects 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 102100040247 Tumor necrosis factor Human genes 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 210000002381 plasma Anatomy 0.000 description 9
- 208000009386 Experimental Arthritis Diseases 0.000 description 8
- 210000002683 foot Anatomy 0.000 description 8
- 210000004698 lymphocyte Anatomy 0.000 description 8
- 210000000822 natural killer cell Anatomy 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 description 7
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 7
- 108010002350 Interleukin-2 Proteins 0.000 description 7
- 108090001005 Interleukin-6 Proteins 0.000 description 7
- 229960004397 cyclophosphamide Drugs 0.000 description 7
- 210000003743 erythrocyte Anatomy 0.000 description 7
- 230000002949 hemolytic effect Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 6
- 108010002352 Interleukin-1 Proteins 0.000 description 6
- 102000000589 Interleukin-1 Human genes 0.000 description 6
- 239000012980 RPMI-1640 medium Substances 0.000 description 6
- 210000000683 abdominal cavity Anatomy 0.000 description 6
- 206010003246 arthritis Diseases 0.000 description 6
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 6
- 230000034994 death Effects 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 210000000265 leukocyte Anatomy 0.000 description 6
- 210000003024 peritoneal macrophage Anatomy 0.000 description 6
- 230000008961 swelling Effects 0.000 description 6
- 206010020880 Hypertrophy Diseases 0.000 description 5
- 208000004044 Hypesthesia Diseases 0.000 description 5
- 206010023232 Joint swelling Diseases 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 239000000835 fiber Substances 0.000 description 5
- 208000034783 hypoesthesia Diseases 0.000 description 5
- 231100000862 numbness Toxicity 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 208000008423 pleurisy Diseases 0.000 description 5
- 238000003825 pressing Methods 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 210000001541 thymus gland Anatomy 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 108700031361 Brachyury Proteins 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 244000182216 Mimusops elengi Species 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000004856 capillary permeability Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000003292 glue Substances 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 4
- 230000000242 pagocytic effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 210000004988 splenocyte Anatomy 0.000 description 4
- 210000001258 synovial membrane Anatomy 0.000 description 4
- 210000002437 synoviocyte Anatomy 0.000 description 4
- 230000007306 turnover Effects 0.000 description 4
- 241000416162 Astragalus gummifer Species 0.000 description 3
- 206010003694 Atrophy Diseases 0.000 description 3
- 206010014025 Ear swelling Diseases 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 229920001615 Tragacanth Polymers 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 210000003056 antler Anatomy 0.000 description 3
- 230000037444 atrophy Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000000845 cartilage Anatomy 0.000 description 3
- 239000012531 culture fluid Substances 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 229960003444 immunosuppressant agent Drugs 0.000 description 3
- 230000001861 immunosuppressant effect Effects 0.000 description 3
- 239000003018 immunosuppressive agent Substances 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 231100000053 low toxicity Toxicity 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 210000000115 thoracic cavity Anatomy 0.000 description 3
- 239000000196 tragacanth Substances 0.000 description 3
- 235000010487 tragacanth Nutrition 0.000 description 3
- 229940116362 tragacanth Drugs 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 2
- 108090000371 Esterases Proteins 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 206010018691 Granuloma Diseases 0.000 description 2
- 206010027336 Menstruation delayed Diseases 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 108010058846 Ovalbumin Proteins 0.000 description 2
- 101150085390 RPM1 gene Proteins 0.000 description 2
- 241000333599 Silvetia siliquosa Species 0.000 description 2
- 241000545405 Tripterygium Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 210000004100 adrenal gland Anatomy 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 210000000544 articulatio talocruralis Anatomy 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 210000003321 cartilage cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 150000002338 glycosides Chemical group 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 208000018937 joint inflammation Diseases 0.000 description 2
- 210000000627 locus coeruleus Anatomy 0.000 description 2
- 229940092253 ovalbumin Drugs 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 210000004180 plasmocyte Anatomy 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 210000005222 synovial tissue Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 1
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 101100322249 Caenorhabditis elegans lev-1 gene Proteins 0.000 description 1
- 206010067632 Cartilage atrophy Diseases 0.000 description 1
- 241000816459 Colquhounia coccinea Species 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000134884 Ericales Species 0.000 description 1
- 235000009161 Espostoa lanata Nutrition 0.000 description 1
- 240000001624 Espostoa lanata Species 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Natural products C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 235000002710 Ilex cornuta Nutrition 0.000 description 1
- 241001310146 Ilex cornuta Species 0.000 description 1
- 244000283207 Indigofera tinctoria Species 0.000 description 1
- 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 description 1
- 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 206010060820 Joint injury Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 235000010326 Osmanthus heterophyllus Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 244000144987 brood Species 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 210000000078 claw Anatomy 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 125000000853 cresyl group Chemical group C1(=CC=C(C=C1)C)* 0.000 description 1
- 239000000430 cytokine receptor antagonist Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- ZBZFFMBWUCAHIW-UHFFFAOYSA-L disodium propan-2-one sulfate Chemical compound [Na+].[Na+].CC(C)=O.[O-]S([O-])(=O)=O ZBZFFMBWUCAHIW-UHFFFAOYSA-L 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 235000015073 liquid stocks Nutrition 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000008570 maxingshigan Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 230000003405 preventing effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 239000003848 thrombocyte activating factor antagonist Substances 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/37—Celastraceae (Staff-tree or Bittersweet family), e.g. tripterygium or spindletree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
- A61K36/296—Epimedium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/43—Cuscutaceae (Dodder family), e.g. Cuscuta epithymum or greater dodder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (18)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2002/000246 WO2003086425A1 (fr) | 2002-04-09 | 2002-04-09 | Médicament contre les rhumatismes et procédé de production |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1622819A CN1622819A (zh) | 2005-06-01 |
CN100502911C true CN100502911C (zh) | 2009-06-24 |
Family
ID=29220566
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB028286421A Expired - Lifetime CN100502911C (zh) | 2002-04-09 | 2002-04-09 | 一种抗风湿药物及其制备方法 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20050220906A1 (zh) |
EP (1) | EP1510217B1 (zh) |
JP (1) | JP4413013B2 (zh) |
KR (1) | KR100811873B1 (zh) |
CN (1) | CN100502911C (zh) |
AU (1) | AU2002254842B2 (zh) |
CA (1) | CA2481459C (zh) |
HK (1) | HK1074792A1 (zh) |
WO (1) | WO2003086425A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105579039A (zh) * | 2013-08-23 | 2016-05-11 | 北京珅奥基医药科技有限公司 | 阿可拉定在制备用于治疗flt-3有关疾病的药物中的用途 |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100803577B1 (ko) * | 2005-11-30 | 2008-02-15 | (주)아모레퍼시픽 | 이카린의 가수분해물을 함유하는 화장료용 조성물 |
US20070259058A1 (en) * | 2006-05-04 | 2007-11-08 | Rulin Xiu | Morinda herbal extracts and compositions thereof |
KR20080025960A (ko) * | 2006-09-19 | 2008-03-24 | (주)아모레퍼시픽 | 이카리시드 ⅰⅰ의 제조 방법 및 이를 함유하는 미백용조성물 |
KR100821683B1 (ko) * | 2006-11-01 | 2008-04-15 | 우석대학교 산학협력단 | 이카리사이드 Ⅱ (icariside Ⅱ)를 유효성분으로 하는 혈관 형성 장애 관련 질환의 예방 및 치료용 조성물 |
CN101843629B (zh) * | 2010-06-11 | 2012-03-14 | 首都医科大学宣武医院 | 淫羊藿苷和含有淫羊藿苷的淫羊藿黄酮的新用途 |
CN102526387B (zh) * | 2012-02-27 | 2014-01-15 | 天津中医药大学 | 一种治疗早期糖尿病足的药物组合物及制备方法 |
CN108272906A (zh) * | 2018-02-08 | 2018-07-13 | 珠海宝石康科技有限公司 | 一种火陨石酒及其制备方法 |
CN109187810B (zh) * | 2018-10-29 | 2021-06-08 | 广州白云山陈李济药厂有限公司 | 一种治疗类风湿性关节炎中药组合物的检测方法 |
CN112138134B (zh) * | 2020-10-23 | 2021-10-22 | 国康堂(北京)文化传播有限公司 | 一种治疗妇科病的分周期中药敷贴及其制备方法 |
CN112899217A (zh) * | 2021-01-29 | 2021-06-04 | 江西中医药大学 | 含药肝孵育液药理法及麻杏石甘汤含药肝孵育液制备方法 |
CN115501242B (zh) * | 2022-11-07 | 2023-06-09 | 新乡医学院 | 箭藿苷a在制备治疗炎症性疾病的药物中的应用 |
CN116850221B (zh) * | 2023-07-20 | 2024-06-11 | 山东省科学院菏泽分院 | 一种牡丹雄蕊菟丝子复合物及其制备方法和应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1088801A (zh) * | 1993-01-01 | 1994-07-06 | 中国人民解放军第一军医大学 | 治疗顽痹、特别是ra和as的中成药金关片及其制法 |
CN1347711A (zh) * | 2000-10-09 | 2002-05-08 | 四川省中药研究所 | 一种抗风湿药物及其制备方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1058879C (zh) | 1996-06-26 | 2000-11-29 | 内蒙古阿拉善苁蓉集团有限责任总公司 | 一种苁蓉酒 |
CN1085085C (zh) | 1997-08-28 | 2002-05-22 | 徐瑞新 | 一种治疗风湿病的中药及其制作工艺 |
-
2002
- 2002-04-09 AU AU2002254842A patent/AU2002254842B2/en not_active Expired
- 2002-04-09 WO PCT/CN2002/000246 patent/WO2003086425A1/zh active Application Filing
- 2002-04-09 EP EP02724085.2A patent/EP1510217B1/en not_active Expired - Lifetime
- 2002-04-09 CA CA002481459A patent/CA2481459C/en not_active Expired - Lifetime
- 2002-04-09 CN CNB028286421A patent/CN100502911C/zh not_active Expired - Lifetime
- 2002-04-09 KR KR1020047016140A patent/KR100811873B1/ko active IP Right Grant
- 2002-04-09 JP JP2003583444A patent/JP4413013B2/ja not_active Expired - Lifetime
- 2002-04-09 US US10/510,617 patent/US20050220906A1/en not_active Abandoned
-
2005
- 2005-08-17 HK HK05107161.3A patent/HK1074792A1/xx not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1088801A (zh) * | 1993-01-01 | 1994-07-06 | 中国人民解放军第一军医大学 | 治疗顽痹、特别是ra和as的中成药金关片及其制法 |
CN1347711A (zh) * | 2000-10-09 | 2002-05-08 | 四川省中药研究所 | 一种抗风湿药物及其制备方法 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105579039A (zh) * | 2013-08-23 | 2016-05-11 | 北京珅奥基医药科技有限公司 | 阿可拉定在制备用于治疗flt-3有关疾病的药物中的用途 |
Also Published As
Publication number | Publication date |
---|---|
WO2003086425A1 (fr) | 2003-10-23 |
CN1622819A (zh) | 2005-06-01 |
EP1510217A1 (en) | 2005-03-02 |
JP4413013B2 (ja) | 2010-02-10 |
CA2481459C (en) | 2009-12-15 |
HK1074792A1 (en) | 2005-11-25 |
US20050220906A1 (en) | 2005-10-06 |
EP1510217A4 (en) | 2007-08-01 |
JP2005530727A (ja) | 2005-10-13 |
CA2481459A1 (en) | 2003-10-23 |
KR20040101427A (ko) | 2004-12-02 |
EP1510217B1 (en) | 2015-11-11 |
AU2002254842A1 (en) | 2003-10-27 |
AU2002254842B2 (en) | 2008-05-29 |
KR100811873B1 (ko) | 2008-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7662412B2 (en) | Traditional Chinese medicine composition to treat rheumatoid arthritis and preparation method thereof | |
CN100502911C (zh) | 一种抗风湿药物及其制备方法 | |
CN105381334A (zh) | 一种治疗脂肪肝的中药组合物、制剂及制备方法 | |
CN102824579A (zh) | 一种治疗痛风的药物及其制备方法 | |
US8003139B2 (en) | Pharmaceutical composition for treating rheumatism, and method of making same | |
CN102048902B (zh) | 一种治疗肝炎的中药组合物、提取物及制备方法、应用和剂型 | |
CN101647951B (zh) | 一种中药组合物及其制备方法和应用 | |
CN101810686A (zh) | 一种用于治疗类风湿关节炎的配伍组合物及其制备方法 | |
CN101505779A (zh) | 一种降血脂组合物及其应用 | |
CN101129974A (zh) | 一种治疗肝病的中药组合物及制备方法 | |
CN102885928A (zh) | 一种治疗黄疸的中药注射剂及其制备方法 | |
CN110025652A (zh) | 一种防治肝损伤的鸡骨草提取物组合物、制备方法及其应用 | |
CN1219532C (zh) | 一种治疗妇科疾病的中药及其制备方法 | |
CN101455778B (zh) | 一种清热利咽的中药制剂及其制备方法 | |
CN101011543B (zh) | 一种新的抗肿瘤药物组合物 | |
CN112807397A (zh) | 一种治疗慢性肾炎的中药组合物及其制备方法和应用 | |
CN102973676B (zh) | 一种防治心血管疾病的药物及其制备方法 | |
CN109692203A (zh) | 一种具有抗痛风作用的药物组合物 | |
CN100333751C (zh) | 治疗淤胆型肝炎的中药及其制备方法 | |
CN1207009C (zh) | 一种抗风湿药物及其制备方法 | |
CN102670746B (zh) | 一种用于***的抗血小板活化中药组合物 | |
CN102139077B (zh) | 治疗痛风的药物及其制备方法 | |
CN1579515A (zh) | 一种治疗子宫肌瘤的药物及其制备方法 | |
CN108175819A (zh) | 一种用于治疗白内障的中药组合物及其制备方法和用途 | |
CN101991678A (zh) | 茜草在制备预防和治疗肾脏疾病的药物方面的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1074792 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1074792 Country of ref document: HK |
|
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: 610041 No. four, South Renmin Road, Sichuan, Chengdu province 51 Patentee after: Sichuan Traditional Chinese Medicine Institute Patentee after: GUANGZHOU CHENLIJI PHARMACEUTICAL FACTORY Address before: 610041 No. four, South Renmin Road, Sichuan, Chengdu province 51 Patentee before: Sichuan Traditional Chinese Medicine Institute Patentee before: Guangzhou Chenliji Pharmaceutical Factory |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20090624 |